Pipeline

Life sciences are radically improving the chances of treatment, even for diseases that have yet to find therapeutic answers. Thanks to new knowledge of biotechnology, ever-increasing computing power and the advancement of artificial intelligence, we will be able to respond to patients' needs even faster.

Discover Our Pipeline

Clinical Pipeline

With our research and development pipeline, we target some of the highest-needing therapeutic areas.

Eye

Molecule	Therapeutic areas	Preclinical Phase 1 Phase 2 Phase 3 Marketed
Cenergermin-bkbj	Neurotrophic Keratitis (NK)
Cenergermin-bkbj	Persistent Corneal Epithelial Defect (PCED)
Cenergermin-bkbj	Optic neuropathies
DFL 24498	Atopic Keratoconjunctivitis (AKC)
Undisclosed molecule	Ocular Graft vs Host disease (oGvHD)

Cenergermin-bkbj

Therapeutic areas: Neurotrophic Keratitis (NK)

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Cenergermin-bkbj

Therapeutic areas: Persistent Corneal Epithelial Defect (PCED)

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Cenergermin-bkbj

Therapeutic areas: Optic neuropathies

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

DFL 24498

Therapeutic areas: Atopic Keratoconjunctivitis (AKC)

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Undisclosed molecule

Therapeutic areas: Ocular Graft vs Host disease (oGvHD)

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Brain

Molecule	Therapeutic areas	Preclinical Phase 1 Phase 2 Phase 3 Marketed
DFB-000002	CNS indication 1
DFB-000002	CNS indication 2
DFB-000002	CNS indication 3

DFB-000002

Therapeutic areas: CNS indication 1

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

DFB-000002

Therapeutic areas: CNS indication 2

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

DFB-000002

Therapeutic areas: CNS indication 3

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

Pain

Molecule	Therapeutic areas	Preclinical Phase 1 Phase 2 Phase 3 Marketed
DF 2755A	Chronic Pain
DFL 23693	Osteoarthritis

DF 2755A

Therapeutic areas: Chronic Pain

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

DFL 23693

Therapeutic areas: Osteoarthritis

Project Status:

Preclinical:
Phase 1:
Phase 2:
Phase 3:

"We must always return to basic science with fresh new eyes."

Marcello Allegretti,Chief Scientific Officer

“Our pipeline is rooted in rigorous science and inspired by the transformative potential of NGF and other innovative platforms to redefine how we treat diseases of the eye, the brain, and pain.”

Ahmed Enayetallah, Chief Development Officer